Search & Analyze

Astrazeneca Pharma India Ltd.

HealthcarePharmaceuticals & Drugs

www.astrazenecaindia.com/india BSE: 506820NSE: ASTRAZEN

₹6,719.90BSE0.14%

17 Sep, 10:21 AM

₹6,719.90

₹16.78K Cr

98.91

18.55

23.02%

₹6,719.90

₹6,700.00

₹9,850.00

₹6,621.00

Customise metrics bar

Price Performance

Peer Comparison

Name
SUN PHARMA. SUNPHARMA	1,863.00	148.56	4,46,996.10	0.86	1,115.14	49.67%	5,741.13	2.61%	13.27
DIVI'S LAB. DIVISLAB	9,291.65	83.04	2,46,664.11	0.33	891.00	59.96%	2,974.00	26.18%	21.89
TORRENT PHAR TORNTPHARM	4,821.95	86.01	1,83,411.48	0.79	492.00	-10.71%	4,158.00	58.94%	19.77
ZYDUSLIFE ZYDUSLIFE	1,113.15	31.36	1,11,037.14	0.09	339.60	-11.72%	2,872.20	10.97%	16.05
CIPLA LTD. CIPLA	1,357.35	35.73	1,09,654.67	0.96	862.16	-33.84%	5,077.68	0.62%	14.04
LAURUSLABS LAURUSLABS	1,934.20	118.03	1,04,507.19	0.10	289.96	83.59%	1,757.16	22.64%	16.08
DR.REDDY'S DRREDDY	1,153.45	144.14	96,276.20	0.70	404.70	-86.33%	5,136.60	-34.23%	12.67
Astrazeneca Pharma India Ltd. ASTRAZEN	6,719.90	98.91	16,777.00	0.54	37.93	-32.06%	682.79	29.73%	31.24

Quarterly Results

consolidated figures in ₹ Crores · Quarterly

Particulars	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	383.20	387.52	408.00	440.29	480.48	526.31	559.09	611.57	578.61	682.79
Expenses	333.81	349.45	355.46	363.30	394.11	445.20	483.91	566.74	517.70	633.85
	49.39	38.07	52.54	76.99	86.37	81.11	75.18	44.83	60.91	48.94
	12.89%	9.82%	12.88%	17.49%	17.98%	15.41%	13.45%	7.33%	10.53%	7.17%
	8.66	-49.21	8.15	-25.57	10.47	10.88	0.88	6.61	4.87	8.99
Interest	-0.07	0.11	0.34	0.33	0.68	0.72	0.67	1.06	2.04	1.95
	3.76	3.91	9.32	9.07	17.69	16.57	2.57	3.84	5.60	5.23
	54.36	-15.16	51.03	42.02	78.47	74.70	72.82	46.54	58.14	50.75
	27.37%	22.23%	24.69%	26.58%	25.77%	25.26%	25.54%	29.97%	22.81%	25.26%
	39.48	-11.79	38.43	30.85	58.25	55.83	54.22	32.59	44.88	37.93
	15.79	-4.72	15.37	12.34	23.30	22.33	21.69	13.04	17.95	15.17

Profit & Loss

consolidated figures in ₹ Crores · Annual

Particulars	FY 2021-22 (Mar)	FY 2022-23 (Mar)	FY 2023-24 (Mar)	FY 2024-25 (Mar)	FY 2025-26 (Mar)
No of Months	12.00	12.00	12.00	12.00	12.00
INCOME :
	809.45	1,007.61	1,302.14	1,722.70	2,281.84
	805.60	1,002.97	1,295.53	1,716.29	2,275.58
EXPENDITURE :
Increase/Decrease in Stock	14.47	-48.86	-33.77	-332.94	-488.37
Raw Material Consumed	290.81	404.08	623.80	1,290.73	1,868.91
Power & Fuel Cost	8.10	5.54	4.87	5.30	2.88
Employee Cost	230.21	259.10	241.45	257.44	264.38
Other Manufacturing Expenses	57.12	76.04	89.46	48.57	112.23
General and Administration Expenses	40.04	56.66	66.30	75.41	81.45
Selling and Distribution Expenses	62.09	71.57	97.48	103.93	139.85
Miscellaneous Expenses	16.58	13.72	21.49	13.88	32.22
	719.42	837.85	1,111.08	1,462.32	2,013.55
Operating Profit (Excl OI)	86.18	165.12	184.45	253.97	262.03
	14.76	26.10	34.80	40.63	28.49
	100.94	191.22	219.25	294.60	290.52
Interest	0.95	0.63	1.20	1.46	4.49
PBDT	99.99	190.59	218.05	293.14	286.03
	16.95	16.26	14.94	39.99	28.58
Profit Before Taxation & Exceptional Items	83.04	174.33	203.11	253.15	257.45
Exceptional Income / Expenses		-40.23	16.43	-96.79	-5.25
	83.04	134.10	219.54	156.36	252.20
Provision for Tax	21.44	34.81	58.03	40.62	64.68
	61.60	99.29	161.51	115.74	187.52
Extra items				0.00	0.00
Consolidated Net Profit	61.60	99.29	161.51	115.74	187.52
Profit Balance B/F	324.10	378.96	455.64	578.15	632.72
Appropriations	385.70	478.25	617.15	693.89	820.24
Equity Dividend %	500.00%	800.00%	1,200.00%	1,600.00%	1,800.00%
	24.64	39.72	64.60	46.30	75.01
Adjusted EPS	24.64	39.72	64.60	46.30	75.01

Balance Sheet

consolidated figures in ₹ Crores

Particulars	FY 2021-22 (Mar)	FY 2022-23 (Mar)	FY 2023-24 (Mar)	FY 2024-25 (Mar)	FY 2025-26 (Mar)
	5.00	5.00	5.00	5.00	5.00
Share Warrants & Outstandings	1.95	2.57	3.29	7.15	6.51
Total Reserves	504.44	581.12	703.63	758.20	861.28
Reserve excluding Revaluation Reserve	504.44	581.12	703.63	758.20	861.28
Revaluation reserve				0.00
	511.39	588.69	711.92	770.35	872.79
Deferred Tax Assets / Liabilities	-16.30	-20.67	-21.25	-41.56	-37.80
Other Long Term Liabilities	5.02	3.69	2.78	38.45	118.67
Long Term Provisions	84.91	85.97	116.30	162.24	313.62
Total Non-Current Liabilities	73.63	68.99	97.83	159.13	394.49
Trade Payables	190.44	227.88	196.51	456.30	782.70
Other Current Liabilities	94.23	111.95	110.53	129.53	137.78
Short Term Provisions	107.63	144.57	160.11	322.32	189.02
Total Current Liabilities	392.30	484.40	467.15	908.15	1,109.50
Total Liabilities	977.32	1,142.08	1,276.90	1,837.63	2,376.78
Gross Block	168.83	179.12	187.13	217.61	184.76
Less: Accumulated Depreciation	94.34	110.26	120.45	153.37	67.29
Net Block	74.49	68.86	66.68	64.24	117.47
Capital Work in Progress	2.20	1.33	0.27
Long Term Investment				0.00
Long Term Loans & Advances	135.31	135.95	167.21	222.24	387.69
Other Non Current Assets				3.65	4.00
Total Non-Current Assets	212.00	206.14	234.16	290.13	509.16
Inventories	140.22	190.21	227.88	548.50	1,027.33
Sundry Debtors	85.89	107.52	153.13	184.88	213.68
Cash and Bank	448.46	500.48	505.84	536.70	448.62
Other Current Assets	12.64	13.56	13.23	16.20	12.22
Short Term Loans and Advances	78.11	124.17	142.66	261.22	158.03
Total Current Assets	765.32	935.94	1,042.74	1,547.50	1,859.88
Net Current Assets (Including Current Investments)	373.02	451.54	575.59	639.35	750.38
Total Assets	977.32	1,142.08	1,276.90	1,837.63	2,376.78
Contingent Liabilities	122.74	131.62	137.64	98.41	121.23
Total Debt	0.00	0.00	0.00	0.00	0.00
	203.78	234.45	283.45	305.28	346.51
Adjusted Book Value	203.78	234.45	283.45	305.28	346.51

Cash Flow

consolidated figures in ₹ Crores

Particulars	FY 2021-22 (Mar)	FY 2022-23 (Mar)	FY 2023-24 (Mar)	FY 2024-25 (Mar)	FY 2025-26 (Mar)
No of Months	12.00	12.00	12.00	12.00	12.00
	83.04	134.10	219.54	156.36	252.20
Adjustment	9.66	-4.80	-7.07	76.41	33.35
Changes In working Capital	32.89	-30.19	-128.17	-103.22	-217.38
Cash Flow after changes in Working Capital	125.59	99.11	84.30	129.55	68.17
Cash Flow from Operating Activities	100.80	58.29	27.87	65.36	-15.14
Cash Flow from Investing Activities	4.74	18.11	21.74	30.80	18.69
Cash Flow from Financing Activitie	-9.46	-24.48	-44.38	-65.59	-91.97
Net Cash Inflow / Outflow	96.08	51.92	5.23	30.57	-88.42
Opening Cash & Cash Equivalents	352.34	448.42	500.34	505.57	536.14
Closing Cash & Cash Equivalent	448.42	500.34	505.57	536.14	447.72

Ratios

Valuation

98.91

18.55

63.70

6.90

67.85

361.68

Profitability

23.02

31.24

8.90

11.48

8.22

Leverage & Liquidity

0.00

1.68

57.17

Returns

0.54

1.08

Shareholding Pattern

Numbers in percentages

Particulars	Jun '24	Sep '24	Dec '24	Mar '25	Jun '25	Sep '25	Dec '25	Mar '26	Jun '26
	75.00	75.00	75.00	75.00	75.00	75.00	75.00	75.00	75.00
	7.79	8.00	8.14	7.53	7.58	7.99	8.26	8.56	8.75
	17.21	17.01	16.87	17.48	17.42	17.01	16.74	16.44	16.25
	25.00	25.00	25.00	25.00	25.00	25.00	25.00	25.00	25.00
No. of Shareholders	27,169	27,615	27,322	32,466	34,378	32,914	31,551	29,007	29,338

Corporate Actions

Showing: All

Date	Type	Details	Ex-Date	Record Date
2026-08-04	Board Meeting	Quarterly Results
2026-07-21	Ex Dividend	Rs.36.0000 per share(1800%)Final Dividend	2026-07-31	2026-07-31
2026-07-20	AGM

Insider Trading

Date	Person	Category	Transaction Type	Shares	Value (₹)

No insider trading data available.

Sector Overview

HealthcarePharmaceuticals & Drugs

Astrazeneca Pharma India Ltd. operates in the Healthcare sector under the Pharmaceuticals & Drugs industry. This sector is one of the key drivers of the Indian economy and is closely tracked by the relevant Nifty sectoral index.

Company Profile

Corporate information and contact details

Key Management

8 members across the board and senior leadership

Tanya Sanish

Company Secretary & Compliance Officer

—

Shilpa Divekar Nirula

Chairperson

₹11.00 L

Mar '26

Revathy Ashok

Non Executive Independent Director

₹14.00 L

Mar '26

Monica Widhani

Non Executive Independent Director

₹14.00 L

Mar '26

Praveen Rao Akkinepally

Managing Director

₹3.89 Cr

Mar '26

Bhavana Agrawal

Whole Time Director

₹2.56 Cr

Mar '26

Hooi-Bien Chuah

Non Executive Director

—

Praveen K Mittal

Director - Corporate Affairs

—

ASTRAZEN Latest News

News

9 of 9 articles

EQUITY15 Sept 2026 · 12:55

AstraZeneca Pharma India informs about resignation of senior management personnel

EQUITY11 Aug 2026 · 09:43

AstraZeneca Pharma India informs about press release

EQUITY10 Aug 2026 · 12:52

AstraZeneca Pharma rises on getting CDSCO nod to market Enhertu for additional indication

The receipt of this permission paves way for the marketing of Trastuzumab Deruxtecan 100mg/5mL lyophilized powder for concentrate for solution for infusion in India

COMPANY10 Aug 2026 · 12:28

AstraZeneca Pharma gets CDSCO nod to market Enhertu for additional indication

The receipt of this permission paves way for the marketing of Trastuzumab Deruxtecan 100mg/5mL lyophilized powder for concentrate for solution for infusion in India

EQUITY29 Jul 2026 · 09:54

AstraZeneca Pharma India informs about certificate

EQUITY21 Jul 2026 · 12:02

AstraZeneca Pharma India informs about resignation of CFO

EQUITY12 Jun 2026 · 15:50

AstraZeneca Pharma India informs about resignation of senior management personnels

EQUITY11 Jun 2026 · 11:39

AstraZeneca Pharma India informs about updates

EQUITY26 May 2026 · 19:16

Astrazeneca Pharma I reports Profit after tax of Rs 448.80 Mln, in the March 2026 quarter

ASTRAZEN

₹6,719.90

+0.14%